Gilead Sciences, Inc. (NASDAQ:GILD) – Stock analysts at Svb Leerink dropped their Q2 2019 earnings per share (EPS) estimates for shares of Gilead Sciences in a research note issued on Tuesday, May 21st. Svb Leerink analyst G. Porges now expects that the biopharmaceutical company will post earnings per share of $1.72 for the quarter, down from their previous forecast of $1.73. Svb Leerink also issued estimates for Gilead Sciences’ Q3 2019 earnings at $1.72 EPS, Q4 2019 earnings at $1.67 EPS, FY2019 earnings at $6.79 EPS, FY2020 earnings at $6.87 EPS, FY2021 earnings at $7.06 EPS, FY2022 earnings at $7.33 EPS and FY2023 earnings at $7.70 EPS.
A number of other research analysts have also issued reports on GILD. Citigroup reiterated a “buy” rating and set a $100.00 price target on shares of Gilead Sciences in a research report on Tuesday, February 5th. Wells Fargo & Co reduced their price target on Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating for the company in a research report on Tuesday, February 5th. Raymond James set a $90.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, February 5th. Maxim Group set a $84.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, February 5th. Finally, BidaskClub downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, February 7th. Nine investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $80.57.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.53 by $0.23. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The company had revenue of $5.28 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the previous year, the firm posted $1.48 EPS. The firm’s quarterly revenue was up 3.8% on a year-over-year basis.
Large investors have recently bought and sold shares of the stock. Athena Capital Advisors LLC purchased a new position in Gilead Sciences in the fourth quarter valued at about $27,000. Capital Financial Planning LLC purchased a new position in Gilead Sciences in the fourth quarter valued at about $27,000. Creative Financial Designs Inc. ADV grew its stake in Gilead Sciences by 55.9% in the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 165 shares in the last quarter. Claybrook Capital LLC purchased a new position in Gilead Sciences in the fourth quarter valued at about $32,000. Finally, Trustcore Financial Services LLC purchased a new position in Gilead Sciences in the first quarter valued at about $34,000. 78.68% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Richard James Whitley sold 9,534 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $65.48, for a total transaction of $624,286.32. Following the transaction, the director now directly owns 34,669 shares of the company’s stock, valued at $2,270,126.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John Francis Cogan sold 2,868 shares of the company’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $64.89, for a total value of $186,104.52. Following the transaction, the director now directly owns 57,728 shares in the company, valued at $3,745,969.92. The disclosure for this sale can be found here. Insiders have sold 28,602 shares of company stock worth $1,863,445 over the last three months. 0.20% of the stock is owned by insiders.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.75%. The ex-dividend date of this dividend is Thursday, June 13th. Gilead Sciences’s payout ratio is 40.98%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
See Also: How to Trade Using Analysts Ratings
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.